1262. Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019

BACKGROUND: Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor in Phase 3 clinical development for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study reports on interim results from a global surveillance program to...

Descripción completa

Detalles Bibliográficos
Autores principales: Arends, S J Ryan, Butler, Deborah, Scangarella-Oman, Nicole, Castanheira, Mariana, Mendes, Rodrigo E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776182/
http://dx.doi.org/10.1093/ofid/ofaa439.1446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776182/
http://dx.doi.org/10.1093/ofid/ofaa439.1446

Ejemplares similares